KiroVAX 003

Drug Profile

KiroVAX 003

Alternative Names: CT-003; KiroVAX003; TAPA loaded DC vaccine - KiroVAX-003; TAPA loaded dendritic cell vaccine - KiroVAX-003; TAPA pulsed dendritic cell vaccine - KiroVAX-003; TAPA-pulsed DC vaccine - KiroVAX-003; Tumour associated peptide antigen loaded DC vaccine-KiroVAX-003; Tumour associated peptide antigen loaded dendritic cell vaccine - KiroVAX-003; Tumour associated peptide antigen pulsed DC vaccine - KiroVAX-003; Tumour associated peptide antigen pulsed dendritic cell vaccine - KiroVAX-003

Latest Information Update: 24 May 2016

Price : $50

At a glance

  • Originator Kiromic
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 01 Sep 2014 Phase-I clinical trials in Solid tumours in USA (Intradermal)
  • 01 Sep 2014 Phase-I clinical trials in Solid tumours in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top